remain posit follow earn call think beat impli
softer due time also management comment finish near oppos
bottom guidanc rang increment posit pharma remain
solid foot management confid defend profit face potenti
strong softer due time base follow-up convers
management seem better expect impli softer
mere due time recal last quarter management note expect adj
ep back-half without provid quarterli cadenc management back-half
expect remain
confid defend profit face potenti reimburs model
chang management note confid abl defend valu
meaning chang drug price list price collaps net price
management confid base abil adjust contract demonstr
contract rebalanc effort transit buy-and-hold fee-
for-servic fact think rebalanc effort abl
maintain margin renew addit management believ price
defens fair
pharma distribut continu outperform strength core distribut
evidenc volum margin slightli better street management
expect addit despit headwind relat suspens
pharmedium memphi facil pharma oper incom grew y/i y/
exclud profarma brazil addit benefit base key
custom grow faster market specialti distribut anoth
bright spot grown y/i mark consecut quarter
greater revenu growth specialti
memphi facil expect fulli oper management expect memphi
facil fulli oper activ commun
fda two week ago notifi intent resum limit product
commenc commerci distribut month still assum contribut
pharmedium estim assum linear ramp throughout
issu fusion implement lash persist lash drove miss
segment oper profit cost continu higher management anticip
go-liv period taken longer expect migrat exist program
health data new fusion technolog platform last also see slightli slower new
busi develop pipelin market posit note lash continu receiv
high satisfact score partner fusion management pleas contract
pleas see page report import disclosur
posit think on-going transit custom new
price model break specialti result margin expans drive growth
profit addit sourc benefit wbad help drive margin
profit medium-term volum esrx onboard onboard
store acquir also serv near-term tailwind
 statu regard ramp
 progress fusion implement
 top-lin growth driven specialti
includ alliancerx acquisit hd
smith store acquir
 gross margin
 ebit margin
 top-lin growth low-teen due
greater expect growth specialti
 top-lin growth mid-singl digit
due lower brand inflat
 gm due better
expect purchas effici
 sg better expect due
 share come lower due greater
expect share repo
 margin closer due higher
expect gener deflat lower
 sg come wors expect
 share come higher due lower
one three largest pharmaceut distribut compani
 servic pharmaceut manufactur health care provid
pharmaceut suppli channel primarili provid drug distribut relat servic
distribut comprehens offer brand name gener pharmaceut over-the-
counter health care product home health care suppli equip wide varieti
health care provid locat throughout includ acut care hospit
health system independ chain retail pharmaci mail-ord facil physician
clinic altern site facil skill nurs assist live center
updat outlook
management increment posit guidanc although subtl management note
quarter expect near bottom adj ep guidanc rang
slight improv management commentari last quarter
expect adj ep bottom rang
reaction revis guidanc overblown management revis segment
oper incom segment guidanc due higher
cost relat lash chang consolid adj oper incom
guidanc think may overreact downward revis
optic look wors percentag basi oper profit dollar basi
midpoint downward revis amount reduct oper incom
estim off-set slightli improv expect tax
updat estim price
slightli rais adj ep estim lower adj
ep estim lower price target base
revis dcf analysi impli share trade adj ep
estim
million except per-shar data
cowen compani
model assumptionstermin growth depreci chang work capit valuefre free futur excess number per end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig incom cont incom deal-rel incom ex-discontinu average ep ex discontinu chang incom cont ep cont end septemb cowen
million except per-shar data
compani report cowen compani
cost good gross margin ebitda ebit losses/ incom affili exp tax incom conv sub note deal-rel sever litig own net incom deal-rel incom ex-discontinu average ep ex-discontinu chang year-over-year total incom cont ep cont cowen
million
compani report cowen compani
asset receiv net doubt expens current charg total liabil account payabl incom current equiti common paid-in earn comprehens commmon stock total stockhold liabil stockhold liquid ratio current sale purchas acct ratio inventori structur long-term solvenc ratio total debt total interest ratio return commit capit asset averag stockhold equiti cowen
million
compani report cowen compani
income/ loss flow oper activ depreci provis loss account sale invest employe stock defer incom invest impair oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash oper acquisit properti acquisit purchas treasuri dividend common proceeds/ repay debt net increase/ decreas cash equival begin cash equival end summari oper year end septemb cowen
million
compani report cowen compani
activitiesnet loss incom discontinu incom continu adjust reconcil net incom provis loss account provis defer incom employe stock loss dispos properti impair charg equiti investment- lifo expense- pension settlement- includ intang asset loss earli retir debt- chang oper asset liabil account merchandis prepaid expens account payabl accru expens incom net cash provid use oper activ continu net cash provid use oper activ discontinu net cash provid use oper invest activitiescapit acquir compani net cash acquired- proce sale properti equiti investments- proce sale purchas invest secur avail sale- other- net cash provid use invest activ continu net cash provid use invest activ discontinu net cash provid use invest financ activitiesborrow revolv securit credit purchas treasuri defer financ cost exercis warrants- exercis stock dividend common purchas cap call other- net cash provid use financ activ continu net cash provid use financ activ discontinu net cash provid use financ increas cash cash cash equival begin cash equival end fiscal year end septemb cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ credibl
indic enter pharma suppli chain sharp unexpect declin
gener deflat less expect benefit wbad econodisc
